Zymeworks (ZYME) Accounts Payables (2021 - 2026)
Zymeworks (ZYME) posted Accounts Payables of $30.2 million for Q1 2026, down 16.84% sequentially from $36.3 million in Q4 2025, and down 20.92% YoY from $38.2 million in Q1 2025.
Analysis
Zymeworks (ZYME) Accounts Payables (2021 - 2026) Analysis & Trends
Zymeworks has reported Accounts Payables for 6 years, with the latest figure at $30.2 million in Q1 2026.
- Quarterly Accounts Payables fell 20.92% year-over-year to $30.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.2 million (down 20.92% YoY) and the FY2025 annual result came in at $36.3 million, down 39.26% from the prior year.
- Accounts Payables retreated to $30.2 million in Q1 2026 per ZYME's latest filing, from $36.3 million in the prior quarter.
- Over five years, Accounts Payables peaked at $87.5 million in Q4 2022 and troughed at $30.2 million in Q1 2026.
- A 5-year average of $50.4 million and a median of $47.4 million in 2024 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2022 and 2023: Accounts Payables surged 39.3% in 2022, then slumped 47.42% in 2023.
- Over 5 years, Accounts Payables stood at $87.5 million in 2022, then slumped by 47.42% to $46.0 million in 2023, then jumped by 30.11% to $59.8 million in 2024, then sank by 39.26% to $36.3 million in 2025, then retreated by 16.84% to $30.2 million in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $30.2 million, $36.3 million, and $34.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 167.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 88.42 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 470.30 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 108.02 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 35.57 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Zymeworks | 2.13 Bn | 1.86 Bn | - | 27.46 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 27.46 Mn |
| Mar 31, 2026 | 30.23 Mn |
| Dec 31, 2025 | 36.35 Mn |
| Sep 30, 2025 | 34.43 Mn |
| Jun 30, 2025 | 31.00 Mn |
| Mar 31, 2025 | 38.22 Mn |
| Dec 31, 2024 | 59.84 Mn |
| Sep 30, 2024 | 51.71 Mn |
| Jun 30, 2024 | 44.42 Mn |
| Mar 31, 2024 | 47.43 Mn |
| Dec 31, 2023 | 45.99 Mn |
| Sep 30, 2023 | 67.79 Mn |
| Jun 30, 2023 | 69.92 Mn |
| Mar 31, 2023 | 59.25 Mn |
| Dec 31, 2022 | 87.47 Mn |
| Sep 30, 2022 | 52.27 Mn |
| Dec 31, 2021 | 62.79 Mn |